Ophthalmologist Shares Periocular Excision Tips

BY HEIDI SPLETE
Senior Writer

GRAND CAYMAN, CAYMAN ISLANDS — Lid and ocular surface lesions are signs of conditions where the eye and the skin overlap, Dr. Catherine Newton said at the Caribbean Dermatology Symposium. Dr. Newton, a professor of ophthalmology at the University of Louisville (Ky.), presented examples of cases with skin and eye involvement that are not inflammatory diseases, including benign conditions (neoplasms) and potentially serious infections such as herpes.

Dr. Newton presented a case of an 82-year-old man who reported “something blocking his view” during a visit for corneal care. It was a bumpy mass that was diagnosed as a verrucous papilloma.

Cysts and benign neoplasms near the eye are common, Dr. Newton said. An ophthalmologist performed a surgical resection of the verrucous papilloma, and the patient has had no recurrence, she said in an interview.

Another case of a benign neoplasm involved a woman with a bump on the lower left lid (acanthoma). Dr. Newton treated this patient with lidocaine ointment, and she was later able to use a jeweler’s forceps and remove the sac, which spared the patient an excision.

Dr. Newton presented a case of an 11-year-old girl with molluscum contagiosum as an example of an infectious disease that can involve the eyes and skin. Molluscum contagiosum lesions often occur on the faces in children who acquire the infection by nonsexual transmission. The lesions can be mistaken for pustules, but histology data confirm the infection.

She treated the girl by curetting the lesions using local anesthesia, and the lesions have resolved completely. Cryotherapy and a peeling agent such as salicylic acid may also be used to treat molluscum contagiosum lesions.

Goes On Silky Smooth.

NEW Olux-E Foam delivers Class I steroid power in a silky foam uniquely designed for the body.

- Patient-preferred mamilent formulation.
- Ethanol-free and feels soothing on skin.
- Easy to spread over multiple body areas.
- Powerful Class I efficacy across different types of dermatoses.
- Safe and effective for use in patients 12 years of age or older.

*Based on post-study surveys (N=377 and N=376) of patients using a 2-week trial regimen of Olux-E Foam or vehicle foam.

Olux-E Foam is indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 12 years of age or older. Treatment should be limited to 2 consecutive weeks and patients should not use greater than 50 grams per week.

Olux-E Foam has been shown to suppress the hypothalamic-pituitary-adrenal (HPA) axis.

The pooled incidence of local adverse reactions in controlled clinical trials for moderate to severe atopic dermatitis and mild to moderate plaque-type psoriasis with Olux-E Foam was 1.9% for application site atrophy and 1.6% for application site reaction.

Please see following page for important safety information.

For further details, visit www.Olux-E.com.